A phase 1/1b study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors

Authors :: Lyudmilla Bazhenova
J. Oliver
Siqing Fu
Petros Nikolinakos
Albert C. Lockhart
Alexander Drilon
T. Seery
Ding Wang
F. Marwan
Manish R. Patel
Stephen V. Liu
Anthony J. Olszanski
Pratik S. Multani
R. Patel
Source :: European Journal of Cancer. 69:S143
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Subjects :: Cancer Research
Oncology
BRAF inhibitor
business.industry
Phase (matter)
Cancer research
Medicine
In patient
business

Tools